PA8.DE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 Nov 2023 @ 00:36):

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide...

Stats
今日成交量	5 275.00
平均成交量	18 739.00
市值	2.71M
EPS	€0 ( 2024-04-21 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.130
ATR14	€0.380 (105.56%)

音量相关性

長: -0.58 (weak negative)

短: 0.13 (neutral)

Signal:(15.842) Neutral

Paion AG 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Paion AG 相关性 - 货币/商品

-0.64
( weak negative )

-0.62
( weak negative )

0.61
( weak )

-0.55
( weak negative )

-0.23
( neutral )

0.11
( neutral )

Paion AG 财务报表

Annual	2022
营收:	€33.25M
毛利润:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2022
营收:	€33.25M
毛利润:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2021
营收:	€7.13M
毛利润:	€4.05M (56.83 %)
EPS:	€-0.310

FY	2020
营收:	€19.66M
毛利润:	€19.66M (100.00 %)
EPS:	€0.0295

Financial Reports:

No articles found.

Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.